Molecular Imaging 2017

Standard of care: general agreement

• Exclusive Radiochemotherapy • MMC/5FU (or capecitabine) • (CDDP/5FU) • No benefit for neoadjuvant chemotherapy • No benefit for maintenance • IMRT • Can reduce acute toxicity • High gradient dose between tumor and normal tissue • Needs accurate delineation and control • No Gap • Good outcomes: 5-year survival=70 %